据证券之星公开数据整理，近期翰宇药业（300199）发布2025年中报。截至本报告期末，公司营业总收 入5.49亿元，同比上升114.86%，归母净利润1.45亿元，同比上升1504.3%。按单季度数据看，第二季度 营业总收入2.39亿元，同比上升127.07%，第二季度归母净利润7560.02万元，同比上升1919.66%。本报 告期翰宇药业短期债务压力上升，流动比率达0.48。 本次财报公布的各项数据指标表现尚佳。其中，毛利率62.46%，同比增3.96%，净利率26.3%，同比增 713.06%，销售费用、管理费用、财务费用总计1.48亿元，三费占营收比27.02%，同比减57.29%，每股 净资产0.82元，同比减4.01%，每股经营性现金流0.18元，同比增376.42%，每股收益0.16元，同比增 1700.0% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 2.56亿 | 5.49亿 | 114.86% | | 归母净利润（元） | -1035.88万 | 1.45亿 | 1504.30% | | ...

Core Insights - Hanyu Pharmaceutical has entered the dosage maintenance phase for its Semaglutide injection project, with plans to apply for market approval in China by 2026 [1] Company Developments - The company is developing HY3003, a GLP-1R/GIPR/GCGR receptor agonist for weight loss, utilizing AI peptide chip technology for candidate selection [1] - Hanyu has completed preclinical candidate screening and raw material process development, now moving into the raw material pilot scale-up phase [1] - In addition to the weight loss drug, the company is also working on an innovative drug, HY3000 nasal spray, aimed at preventing coronavirus infections, which is currently in Phase III clinical trials [1] Collaborations and Innovations - Hanyu is collaborating with China National Pharmaceutical Group on the research and commercialization of Cannabidiol (CBD) innovative drugs, integrating peptide and small nucleic acid drug technologies [1] - The company has completed enrollment of all participants in the Phase III clinical trial for Semaglutide injection as of January this year and is currently in the follow-up phase [1]